Cost-effectiveness results for cohort of 60-year-old patients with resected colorectal cancer*
| Scenario and strategy | Total cost (US$) | Health effects (QALYs) | Incremental Cost (US$) | Incremental QALYs | ICER (US$/QALY) |
| Stage III patients | |||||
| CTC-based strategy | 121 099 | 8.0721 | |||
| Standard of care | 121 392 | 8.0774 | 293 | 0.0053 | 55 498 |
| Stage II patients | |||||
| CTC-based strategy | 112 300 | 9.3684 | |||
| Standard of care | 112 557 | 9.3748 | 257 | 0.0064 | 40 193 |
*Costs and effects are generated under the assumption of 100% systematic adherence to surveillance. A lower systematic adherence would reduce costs and effects proportionally but ICERs would remain unchanged.
CTC, CT colonography; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.